Insider Buying: Reckitt Benckiser Group Plc (LON:RB) Insider Purchases 809 Shares of Stock

Reckitt Benckiser Group Plc (LON:RB) insider Christopher Sinclair acquired 809 shares of Reckitt Benckiser Group stock in a transaction that occurred on Friday, May 25th. The stock was acquired at an average cost of GBX 6,030 ($80.28) per share, with a total value of £48,782.70 ($64,948.34).

Reckitt Benckiser Group traded up GBX 61 ($0.81), reaching GBX 6,009 ($80.00), on Thursday, according to MarketBeat Ratings. The company’s stock had a trading volume of 1,536,546 shares, compared to its average volume of 1,720,000. Reckitt Benckiser Group Plc has a 52 week low of GBX 5,562 ($74.05) and a 52 week high of GBX 8,110.43 ($107.98).

RB has been the subject of several analyst reports. Liberum Capital reaffirmed a “buy” rating and issued a GBX 8,000 ($106.51) price objective on shares of Reckitt Benckiser Group in a research note on Monday, February 19th. BNP Paribas reduced their price objective on shares of Reckitt Benckiser Group from GBX 7,200 ($95.86) to GBX 6,000 ($79.88) and set a “neutral” rating for the company in a research note on Tuesday, May 8th. Barclays set a GBX 6,400 ($85.21) price objective on shares of Reckitt Benckiser Group and gave the company a “neutral” rating in a research note on Thursday, May 31st. Credit Suisse Group reduced their price objective on shares of Reckitt Benckiser Group from GBX 5,500 ($73.23) to GBX 5,450 ($72.56) and set a “neutral” rating for the company in a research note on Monday, April 30th. Finally, Societe Generale set a GBX 6,500 ($86.54) price objective on shares of Reckitt Benckiser Group and gave the company a “buy” rating in a research note on Thursday, March 22nd. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 7,040.87 ($93.74).

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply